ライフサイエンスコーパス: amputation

1 g following loss of sensory input (e.g., arm amputation).

2 expectancy (on average only 2 years from the amputation).

3 claudication, leg revascularisation, and leg amputation).

4 oke, or major adverse limb events, including amputation).

5 utation or have already undergone a standard amputation.

6 onary revascularization, and lower extremity amputation.

7 synthesis or mitosis in cardiac tissue after amputation.

8 7-fold (95% CI, 18.3-28.1) increased risk of amputation.

9 rget lesion revascularization and from major amputation.

10 Outcomes included 90-day mortality and major amputation.

11 ded participants with known prior lower limb amputation.

12 formed single-cell RNA sequencing after tail amputation.

13 fe care among patients with ESRD who undergo amputation.

14 emic stroke), all-cause mortality, and major amputation.

15 risk factor for diabetic foot ulceration and amputation.

16 a strong association between albuminuria and amputation.

17 cipients and victims of traumatic major limb amputation.

18 nd higher risk of below-knee lower extremity amputation.

19 a major complication after severe trauma or amputation.

20 ality among groups, and no patient underwent amputation.

21 ocedure, wound progression, or subsequent to amputation.

22 ety end point was below-knee lower extremity amputation.

23 s can re-grow many parts of their body after amputation.

24 The primary outcome was major amputation.

25 as major adverse limb events including major amputation.

26 stroke rates, and increased risk of ischemic amputation.

27 cally de-efferented and de-afferented due to amputation.

28 capillary density, motor function, and their amputation.

29 often associated with risk of infection and amputation.

30 he digit tip after distal, but not proximal, amputation.

31 d with high risk of infection and lower-limb amputation.

32 s 5 mg/g was 3.68 (95% CI 3.00-4.52) for leg amputation.

33 as infected foot ulcers, which often lead to amputation.

34 onditions and after exfoliation or appendage amputation.

35 blindness, chronic kidney disease, and limb amputation.

36 incidence of in-hospital mortality and major amputation.

37 somatosensory cortex even decades after arm amputation.

38 panied by a reduction in mortality and major amputation.

39 7 years in four patients after transhumeral amputation.

40 ecisions between attempting limb salvage and amputation.

41 or endovascular surgery and lower extremity amputation.

42 s, and describe the events surrounding major amputation.

43 ardless of time since amputation or level of amputation.

44 mb ischemia patients undergoing a lower-limb amputation.

45 rtality, cardiovascular morbidity, and major amputation.

46 fter dermofasciectomy carries a high risk of amputation.

47 tic foot is a major problem often leading to amputation.

48 1000 person-years, yielding a total of 1185 amputations.

49 not the case, however, with diabetes related amputations.

50 S as a tool to restore somatosensation after amputations.

51 eplicas of the originals even after repeated amputations.

52 inability to work, physical deformities, and amputations.

53 imited treatment options, often resulting in amputations.

54 evices, 0.4% new ostomy procedures, and 0.1% amputations.

55 ctions in all adverse outcomes, except major amputations.

56 vessel immaturity leading to lower extremity amputations.

57 ld higher risk of below-knee lower extremity amputation (0.17 versus 0.09 events per 100 person-years

58 5), surgical bypass (24.6%, n=72), and major amputation (13.0%, n=38).

59 ty (11.8% in 2005 to 9.7% in 2014) and major amputation (19.8% in 2005 to 12.9% in 2014; P value for

60 4.0%; 95% CI, 2.6%-5.4%) and lower extremity amputation (2.3%; 95% CI, 0.8%-3.8%).

61 eries (2.1 +/- 1.3 vs 3.3 +/- 2.3; P < .01), amputations (26.3% vs 83.4%; P < .01), reinfection (38.0

62 nd major adverse limb events including major amputation (32 [1%] vs 60 [2%]; HR 0.54 95% CI 0.35-0.82

63 rterial revascularization or lower extremity amputation, 4.6% died, and the median cost of a readmiss

64 ed major adverse limb events including major amputation (40 [2%] vs 60 [2%]; HR 0.67, 95% CI 0.45-1.0

65 anagliflozin except for an increased risk of amputation (6.3 vs. 3.4 participants per 1000 patient-ye

66 minuria levels including increased risks for amputation across albuminuria subgroups (P heterogeneity

67 ry infections, ketoacidosis, bone fractures, amputations, acute kidney injury, perineal necrotizing f

68 zard ratio, 1.29 [95% CI, 1.03-1.62]), major amputation (adjusted hazard ratio, 4.12 [95% CI, 2.46-6.

69 d HR 3.3, 95% CI 2.4-4.6, P<0.01), and major amputation (adjusted HR 34.2, 95% CI 9.7-20.8, P<0.01).

70 adjusted HR, 0.47; 95% CI, 0.29-0.77), minor amputation (adjusted HR, 0.26; 95% CI, 0.13-0.54), bypas

71 VR group were also less likely to have major amputation (adjusted HR, 0.47; 95% CI, 0.29-0.77), minor

72 , P<0.001) and adjusted risk of 90-day major amputation (adjusted rate ratio, 1.30 [95% CI, 1.14-1.48

73 gnosed in any location increases the risk of amputation alone and in concert with peripheral artery d

74 microvascular disease increases the risk of amputation alone and synergistically increases risk in p

75 Amputation also places a substantial financial burden on

76 cular access devices, ostomy procedures, and amputation) among children surviving hospitalizations wi

77 30 days, and freedom from target limb major amputation and clinically driven target lesion revascula

78 procedure and freedom from target limb major amputation and clinically driven target lesion revascula

79 with diabetes who were undergoing major limb amputation and control subjects.

80 It may lead to amputation and death if not treated in a timely fashion.

81 s well as psychosocial, consequences such as amputation and depression.

82 It is a leading cause of lower-limb amputation and disabling neuropathic pain.

83 We also examined the relationship between amputation and end-of-life care among the patients with

84 bone tumor characterized with a high risk of amputation and malignant morbidity among teenagers and a

85 mory of the new size in subsequent rounds of amputation and regeneration.

86 on in an 8-year-old child with quadrimembral amputations and a previous kidney transplant.

87 ning disease that often result in lower limb amputations and a shortened lifespan.

88 are few therapeutic alternatives, leading to amputations and death.

89 Amputations and recurrences in patients with eumycetoma

90 , AMIs have been implemented only in planned amputations and require healthy distal tissues, whereas

91 r surgical therapy (revascularization and/or amputation) and were discharged alive were identified in

92 fasciitis of a lower extremity that required amputation, and 1 patient required a lower-extremity byp

93 hrodesis, 0.40% (0.30-0.54; 46 patients) for amputation, and 1.33%; (1.13-1.56; 152 patients) for art

94 y with an increased risk of all-cause death, amputation, and a composite of cardiovascular death, myo

95 ic improvement, quality of life, target limb amputation, and all-cause mortality.

96 s the cornerstone of therapy to prevent limb amputation, and both open vascular surgery and endovascu

97 Stenosis >50%, retreatment, major amputation, and critical limb ischemia-related death wer

98 ion) and more events (myocardial infarction, amputation, and major bleeding) by 12 months postrandomi

99 m from a composite of all death, target limb amputation, and target lesion revascularization at 30 da

100 myocardial infarction, transfusion, stroke, amputation, and the composite end points of major advers

101 ronary revascularization and lower extremity amputation, and the majority of bleeding events occur wi

102 major adverse events including death, major amputations, and clinically driven target lesion revascu

103 reductions in myocardial infarction, stroke, amputations, and mortality.

104 unction in degenerative diseases, trauma and amputation; and even augmentation of human cognition.

105 .9-fold (95% CI, 11.3-17.1) elevated risk of amputation; and the combination of peripheral artery dis

106 Minor amputations are often required for tissue loss as a part

107 Over 60% of lower extremity amputations are performed in patients with diabetes and

108 0 days, adverse joint outcomes (arthrodesis, amputation, arthroplasty) within 1 year, and arthroplast

109 alamanders can regenerate entire limbs after amputation as adults, and much recent effort has sought

110 seriously ill patients with ESRD who undergo amputation as well as opportunities to improve their car

111 nt interaction between travel time and major amputation as well as travel time and revascularization

112 Here, the authors use an amputation assay in Xenopus laevis to demonstrate that r

113 Here we use an amputation assay in Xenopus laevis to show that absence

114 0.45 [95% CI, 0.41-0.50]; P<0.001) and major amputation at 90 days (RR, 0.23 [95% CI, 0.21-0.26]; P<0

115 g 125 674 veterans without evidence of prior amputation at baseline, the rate of incident amputation

116 t of injury with either (1) a traumatic limb amputation at or above the knee or elbow or (2) shock de

117 ians (ray-finned fishes), regeneration after amputation at the fin endoskeleton has only been demonst

118 Major amputations (at or above the ankle) limit functional ind

119 ty severity score at predicting the need for amputation [AUROC 0.95 (0.92-0.98) vs 0.74 (0.67-0.80);

120 ive option for patients who have experienced amputation because of trauma.

121 ed as: alive at day 28, <=3 debridements, no amputation beyond first operation, and day 14 mSOFA <=1

122 n revascularization, thrombosis, ipsilateral amputation, binary restenosis, and all-cause mortality a

123 ecently, a long jumper with a below the knee amputation (BKA) achieved jump distances similar to worl

124 showed that cell therapy reduced the risk of amputation by 37%, improved amputation-free survival by

125 ondary outcomes included rates of lower limb amputations, bypass surgical procedures, and peripheral

126 age, female sex, black/Hispanic race, prior amputation, Charlson comorbidity index, and need for hom

127 vascular patients had died or received major amputation compared with 54% of open patients (P < 0.001

128 ndow in early postnatal life wherein partial amputation culminates in a localized regeneration instea

129 Nearly half of the patients who underwent amputation did not receive an invasive vascular procedur

130 The rate of major amputation during the course of the trial was 1.6% overa

131 arization, peripheral revascularization, and amputation during the study.

132 anscriptional responses at 3 and 6-hour post-amputation, especially targeting genes that are implicat

133 rtery disease status on the risk of incident amputation events after adjusting for demographics and c

134 e of death/myocardial infarction/stroke, any amputation, fasciotomy, acute kidney injury, major bleed

135 al limb ischemia, limb revascularization, or amputation for ischemia) and VTE (deep vein thrombosis o

136 , new or worsening congestive heart failure, amputation for ischemic gangrene, and death from cardiov

137 posite outcome of acute limb ischemia, major amputation for vascular causes, myocardial infarction, i

138 as a composite of acute limb ischemia, major amputation for vascular causes, myocardial infarction, i

139 on, stroke, acute limb ischemia, or vascular amputation; for severe bleeding; and for the net clinica

140 At 90 days, amputation-free survival (AFS) and Limb salvage (LS) wer

141 en surgery first was associated with a worse amputation-free survival (hazard ratio, 1.16; 95% CI, 1.

142 This study aims to compare amputation-free survival and reintervention rates in pat

143 used with Kaplan-Meier analysis to determine amputation-free survival and time to reintervention for

144 The amputation-free survival benefit associated with an endo

145 uced the risk of amputation by 37%, improved amputation-free survival by 18%, and improved wound heal

146 al surgical bypass is associated with poorer amputation-free survival compared with an endovascular-f

147 undergoing endovascular repair had improved amputation-free survival compared with open repair at 30

148 ascular approach is associated with improved amputation-free survival over the long term with only a

149 We evaluated amputation-free survival, overall survival, and relative

150 Data on major amputation from a large randomized trial that included a

151 An increased risk of amputation has been observed with canagliflozin in 1 pre

152 While amputation has traditionally been viewed as a failure of

153 injury, prehospital shock, severity of limb amputation, head injury, and torso hemorrhage.

154 se events (HR, 1.07 [95% CI, 0.90-1.26]) and amputation (HR, 1.09 [95% CI, 0.84-1.40]), with no signi

155 ase study in which a person with transradial amputation identified prosthetic hand postures using art

156 Patients with CLTI and/or DFI are at risk of amputations if not treated in a timely manner.

157 her microvascular disease is associated with amputation in a large cohort of veterans to determine wh

158 plucking of zebrafish scales or head or tail amputation in amphioxus and annelids.

159 al artery disease and 10.61 [5.70-19.77] for amputation in eGFR <30 mL/min per 1.73 m(2) plus ACR >/=

160 The risk factors for major amputation in EUCLID patients are similar to previous la

161 amically reestablishes proportionality after amputation in normal animals, indicating STRIPAK repress

162 Tail amputation in pigs appears to evoke acute and sustained

163 i and frequently requires radical surgery or amputation in the absence of appropriate treatment.

164 gi and frequently require radical surgery or amputation in the absence of appropriate treatment.

165 2014 to analyze patterns of lower extremity amputation in the last year of life compared with a para

166 ESRD underwent at least one lower extremity amputation in their last year of life compared with 1% o

167 patients with ESRD undergoes lower extremity amputation in their last year of life.

168 ed in M1 contralateral or ipsilateral to the amputation in three animals.

169 About 85% of lower extremity amputations in diabetes are attributed to deep infection

170 Amputations in patients with diabetes have a devastating

171 lpha (PPARalpha) agonist, reduces lower limb amputations in patients with type 2 diabetes.

172 al Artery Disease) population, subcategorize amputations in the CLI versus no CLI cohorts, and descri

173 e was to describe the incidence and types of amputations in the EUCLID trial (Examining Use of Ticagr

174 agonist and lipid-lowering agent, decreases amputation incidence in patients with diabetes.

175 ctors associated with a lower risk for major amputation included prior statin use.

176 were associated with increased risk of major amputation, including history of amputation, the presenc

177 ere is a myeloid lineage-dependent change in amputation-induced apoptosis levels, which in turn promo

178 Romidepsin treatment for only 1-minute post amputation inhibited regeneration through the first 7 da

179 bypass surgery or angioplasty, limb or foot amputation, intermittent claudication with objective evi

180 directs nerves that lost their target in the amputation into redundant muscles in the region of the s

181 Hand amputation is a highly disabling event, which significan

182 g change observed after unilateral stroke or amputation is a recruitment of bilateral cortical respon

183 Digit tip regeneration following amputation is an innate response in some mammals, includ

184 while prior peripheral revascularization or amputation is associated with greatest risk for major ad

185 Lower extremity amputation is common among patients with ESRD, and often

186 Cortex plasticity after hand amputation is considered harmful, causing phantom limb p

187 The mortality following major amputation is lower in the EUCLID trial compared with re

188 Innate regeneration following digit tip amputation is one of the few examples of epimorphic rege

189 g somatosensory feedback to people with limb amputations is crucial to improve prosthetic control.

190 hough some increase rates of lower-extremity amputation (LEA).

191 ed appendage regeneration, regardless of the amputation level.

192 We show here, using the mouse digit amputation model, that SIRT3 deficiency has no impact on

193 ing a novel in vivo murine hindlimb ischemia-amputation model.

194 37 exposed patients, those who required limb amputation (n = 12/37 [32%]) exhibited lower PCS (34 [IQ

195 Minor amputations not affecting the wound site were also repor

196 lthy distal tissues, whereas the majority of amputations occur in patients who do not have healthy di

197 pterids, regeneration after fin endoskeleton amputation occurs in extant representatives of 2 other n

198 as a composite of acute limb ischemia, major amputation of a vascular cause, myocardial infarction, i

199 red a high-voltage electrical burn requiring amputation of his upper limbs.

200 s, kidney failure, heart attacks, stroke and amputation of lower limbs.

201 a repeat kidney transplant); and 6 required amputation of part of the lower extremity.

202 veloped chronic rejection leading to partial amputation of the allograft.

203 nic allograft vasculopathy eventually led to amputation of the graft.

204 D4, and has a SAXS envelope consistent with amputation of the hairpin containing the dispensable T d

205 ne and fibrous tissues after level-dependent amputation of the murine terminal phalanx and quantified

206 Amputation of the proximal region in mammals is not foll

207 Subsequent amputations of the morphologically normal regenerates in

208 Persons with lower extremity amputation often exhibit abnormal trunk motion, yet unde

209 The influence of the degree of amputation on MNTs was also evaluated by comparing three

210 putation, patients are at heightened risk of amputation on the contralateral leg.

211 d with a risk-adjusted 16% decreased risk of amputation or death compared with open over the study pe

212 leg ischemia only were more likely to avoid amputation or death than patients who also presented wit

213 ons induced by these wounds can lead to limb amputation or even death and urgently require more effec

214 were no significant differences in rates of amputation or fracture.

215 AMI in patients who are undergoing traumatic amputation or have already undergone a standard amputati

216 in the missing hand regardless of time since amputation or level of amputation.

217 confidence interval: 1.28 to 1.40) and major amputation or peripheral revascularization (hazard ratio

218 e of MI or stroke was 9.8% and that of major amputation or peripheral revascularization was 41.9%.

219 nfarction (MI) or stroke and composite major amputation or peripheral revascularization.

220 have lost the use of their hands because of amputation or spinal cord injury can use prosthetic hand

221 After unilateral amputation or stroke, this functional loss disrupts the

222 ctional anatomic units in patients with limb amputations or severe facial tissue loss.

223 chiatric difficulties, the initial trauma of amputation, or adjusting to the transplantation process

224 radiation > 40 Gy, cisplatin >= 600 mg/m(2), amputation, or lung surgery had increased risk for frail

225 rdial infarction, wound infection, bleeding, amputation, or reoperation.

226 events defined as acute limb ischemia, major amputation, or urgent peripheral revascularization for i

227 By demonstrating stable topography despite amputation, our finding questions the extent to which co

228 all-cause mortality and major (above ankle) amputation over 4 years follow-up.

229 amputation at baseline, the rate of incident amputation over a median of 9.3 years of follow-up was 1

230 Importantly, after a major amputation, patients are at heightened risk of amputatio

231 Rates of amputation performed because of nonviable limb tissue we

232 ct whisker processing.SIGNIFICANCE STATEMENT Amputation, peripheral injury, and stroke patients exper

233 Amputations, peripheral revascularization, and limb isch

234 3.7-fold (95% CI, 3.0-4.6) increased risk of amputation; peripheral artery disease alone conferred a

235 velopment and specifically relocalize to the amputation plane of regeneration-competent tadpoles, for

236 feration and migration of progenitors to the amputation plane.

237 e who received placebo but a greater risk of amputation, primarily at the level of the toe or metatar

238 eeding risk related to revascularization and amputation procedures in peripheral artery disease patie

239 However, the amputation rate for re-operation by limited fasciectomy

240 Amputation rate was improved more in trials wherein the

241 reasing rates of in-hospital death and major amputation rates in the United States.

242 Major amputation rates over 4 years were 6.8% with atherectomy

243 ical limb ischemia, high mortality and major amputation rates were observed with minor differences am

244 ions (thromboembolic venous/arterial events, amputations, recurrent/persistent thrombocytopenia, skin

245 h at least 1 amputation, with a total of 407 amputations reported.

246 Penile wounds after traumatic and surgical amputation require reconstruction in the form of autolog

247 gliflozin increased diabetic retinopathy and amputation, respectively.

248 clear whether the below-knee lower extremity amputation risk extends across the class of medication,

249 ptococci was associated with greater risk of amputation (risk ratio, 1.80; 95% confidence interval, 1

250 In individuals with lower-limb amputations, robotic prostheses can increase walking spe

251 dings may therefore explain the reduction in amputations seen in patients with diabetes treated with

252 egenerative) and proximal (non-regenerative) amputations showed significant differences in temporal g

253 tro and in vivo following injection into the amputation site.

254 ecific complications (thromboembolic events, amputation, skin necrosis) occurred in 11.7% of patients

255 Amputation stimulates resident cells within a limited re

256 Amputation stimulates serotonin production in regenerati

257 The mechanisms underlying poor amputation stump healing in the setting of diabetes are

258 N-acetylcysteine accelerates amputation stump healing in the setting of diabetes.

259 Amputation stump tissue perfusion and healing were evalu

260 rs the vascular milieu to improve healing of amputation stumps in diabetes using a novel in vivo muri

261 demonstrate that NAC accelerates healing of amputation stumps in the setting of diabetes and ischemi

262 a failure of therapy, recent developments in amputation surgery and neural interfacing demonstrate im

263 e demonstrate in four people with upper-limb amputation that epidural spinal cord stimulation (SCS),

264 abetic wound care, the significant number of amputations that occur every year demands more effective

265 sk of major amputation, including history of amputation, the presence of diabetes mellitus, baseline

266 able of regenerating fins after endoskeleton amputation: the white convict and the oscar (Cichlidae),

267 We then reveal that upon tail amputation there is a myeloid lineage-dependent change i

268 DAC activity is required at the time of tail amputation to regulate the initial transcriptional respo

269 By contrast, upon amputation, tph1b(+) joint cells give rise to fibroblast

270 mics in persons with unilateral, transtibial amputation (TTA).

271 figuration used by athletes with transtibial amputations (TTAs) likely affects performance.

272 troke), revascularisation, and non-traumatic amputation, up to Dec 31, 2014.

273 nces similar to world-class athletes without amputations, using a carbon fibre running-specific prost

274 After amputation, various cell types contribute to blastema fo

275 e experiment, seven subjects with below-knee amputation walked on the variable-stiffness prosthetic f

276 The annualized rate of major amputation was 0.6% in PAD overall, 3.9% in the CLI at b

277 The annual mortality rate following major amputation was 22.8% in the CLI at baseline group and 16

278 The 30-day mortality rate after major amputation was 6.5% overall, 5.6% in the CLI at baseline

279 Amputation was also associated with a greater likelihood

280 Postrandomization major amputation was analyzed in the EUCLID trial.

281 The occurrence of major amputation was ascertained and defined as the highest le

282 Adjusted for history of PVD, death or limb amputation was more common in patients with COVID-19 (od

283 No major amputation was necessary.

284 ontrast, the adjusted hazard ratio for major amputations was 1.00 (95% CI, 0.90-1.11) when comparing

285 In-hospital mortality and amputation were coprimary outcomes.

286 Perioperative events surrounding major amputation were obtained including acute limb ischemia,

287 Rates of any amputation were similar between the 2 groups (4.7% versu

288 that those who had undergone lower extremity amputation were substantially more likely than those who

289 in exposure in the database, the majority of amputations were observed on canagliflozin.

290 Amputations were performed in 54 patients (2.0%) who rec

291 ; hazard ratio, 1.97; 95% CI, 1.41 to 2.75); amputations were primarily at the level of the toe or me

292 Lower extremity amputations were similarly increased in the secondary an

293 with a substantial improvement prediction of amputation with ACR (difference in c-statistic 0.058, 95

294 as used to associate outcome of death and/or amputation with COVID-19 adjusted according to history o

295 larization, and 236 patients with at least 1 amputation, with a total of 407 amputations reported.

296 e-third of patients with CLI underwent major amputation without a diagnostic angiogram or trial of re

297 Here we show that treating the amputation wound with BMP9 stimulates regeneration of a

298 egeneration response from a non-regenerating amputation wound.

299 We previously discovered that treating digit amputation wounds with BMP2 in neonatal mice stimulates

300 re may be potential to avoid approximately 1 amputation/year for every 2 patients successfully treate